COMPASS Pathways plcCMPS

$12.53+0.59 (+4.94%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$1B

Small-cap

+35%

2020 — today

10-Year Price

-51%

2020 — today

52-Week Range

$2.35$14.19

Current $12.53· 86%

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Valuation in context

P/E ratio

-4.0

N/A

Not meaningful — company is unprofitable

P/B ratio

3.6

Above average

Pricier than usual over the last 10 years

FCF Yield

-13.6%

Above average

Above the 10-year average

Free · No credit card needed

Get alerted when CMPS is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.